2019中文视频免费播放,国产精品娇妻肉欲高潮视频,久久婷婷的综合色丁香五月,国产精品无码久久添爽添片aV

Welcome to the website of Taifang Machinery Co., Ltd!
Suzhou Taifang wire cable machinery Co.,Ltd.
7X24H Service Hotline:

+86-138-1293-0229

Popular keywords:

Contact Us

Suzhou Taifang wire cable machinery Co.,Ltd.

Contacts:Mr.Zhong
Email:121740864@qq.com
Phone:+86-138-1293-0229
ADD:579 Qianjin East Road, Kunshan Development Zone, Jiangsu Province

Location:Home>>News>>Industry News

Kobayashi Pharmaceutical In 'Red Yeast Rice Supplementary Crisis' |5 Deaths and 1.8 Bln Yen Potential Recall Cost Might End Its 26 Years of Net Profit Growth

Release time:2024-04-06Popularity:705

The ongoing health crisis related to Japanese pharmaceutical company Kobayashi Pharmaceutical continues to escalate. On March 30, the health ministry and local authorities on Saturday inspected one of its factories.

Kobayashi Pharmaceutical has so far reported a total of five deaths and the hospitalizations of more than 114 people as possibly linked to the red yeast rice dietary supplements. 

The drugmaker as well as Japan's health ministry said the company's examination unexpectedly found puberulic acid, a natural compound made from blue mold, in the products. The ministry said the substance is a potent antibacterial and antimalarial agent that can be toxic. However, it remains unclear how this highly toxic substance found its way into the products and what impact it has on the kidneys.

Kobayashi Pharmaceutical previously announced a voucher of 2,500 yen (around 16 U.S. dollars) will be provided per item as compensation. There will be no differentiation in compensation for consumers both from home and abroad once the causal relationship is established.

The factory in western Japan, which was making the ingredients of the supplements, shut down in December, and the equipment has since been transferred to Wakayama Prefecture.

The affected health products were primarily produced between April and October 2023, with market availability from July to December 2023. Currently, 173 companies that used Kobayashi Pharmaceutical’s red yeast rice raw material for production are conducting voluntary self-inspections. Out of the 18.5 tons of beni-koji raw material manufactured by Kobayashi Pharmaceutical in 2023, approximately 16.1 tons were sold to external parties.

Additionally, due to the export of red yeast rice raw material, Japanese authorities notified the World Health Organization (WHO) on March 28. The impact of this crisis extends beyond Japan, potentially affecting the global perception of Japanese health products.

Kobayashi Pharmaceutical, a century-old company, heavily relies on health products in its domestic business, accounting for over 50% of its sales. In its 2023 financial report, the company expressed plans to strengthen this category’s overseas development, aiming to increase the share of health product sales in overseas markets from 20% in 2023 to 35% by the end of 2030.

Dr. Wang Yong, initiator and chairman of the China Brand Festival and director of the Brand Alliance, expressed in an interview with the National Business Daily that the impact of the recall on Kobayashi Pharmaceutical is evident. First, sales of affected health products are expected to plummet. Second, the company must allocate substantial funds for product recalls, compensating victims, and improving production processes. Additionally, legal litigation arising from the incident may further strain the company.

From a brand image perspective, this event poses a severe blow to Kobayashi Pharmaceutical. Once a trust crisis takes root, repairing it within a short timeframe becomes challenging. Notably, several Japanese health supplement brands, represented by Kobayashi, have intensified brand promotion and marketing in China in recent years. They have launched numerous popular products, some even earning the moniker “Japanese miracle drugs.” Consequently, this recall incident could erode consumer trust in all Japanese health supplements, potentially impacting long-term sales in the Chinese market.

As the controversy continues to unfold, industry insiders speculate that Kobayashi Pharmaceutical may exit the nutritional supplement and health product market. Institutions, including SMBC Nikko Securities, estimate the recall cost at 1.8 billion Japanese yen (approximately 11.9 million US dollars), with the possibility of further escalation. This projected cost could lead to a 6% decline in the company’s expected net income for the current fiscal year. As a result, Kobayashi Pharmaceutical’s stock price has cumulatively dropped by 15.87% this week.

However, analysts from Morgan Stanley, led by the Wako Sato team, suggest that while the recall is negative news, its impact on Kobayashi Pharmaceutical’s stock price may be transient. They believe that despite the recall’s significant scale, its effects on other Kobayashi products remain limited within a defined range.

Nevertheless, Nikkei News reports that Kobayashi Pharmaceutical has already ceased television advertising and other promotional activities as part of its core marketing strategy. When a company’s image falters, the efficacy of advertisements weakens, and consumers may choose to disengage. The current situation indicates an increasing risk of spillover effects on other goods. If these effects become pronounced, they could undermine the company’s operational foundation.


Q Q
Hotline

Service Hotline

+86-138-1293-0229

WeChat
Suzhou Taifang wire cable machinery Co.,Ltd.
TOP
久久久国产精品无码1区2区| 人妻天堂网| 久久国产精品无码一级毛片| 欧美激情一二三区| 精品亚洲一区二区| 色欲人妻无码| 老熟女太熟了8MAV| 国产在线观看你懂的| 久久久国产三级| 无码国内精品久久综合88 | 久久久久无码精品国产| 国产伦精品一区二区三区视频网站| 亚洲第一页在线观看| 人妻无码精品一区二区| 精品视频免费在线播放| 国产精品欧美三级在线观看| 色噜噜人妻丝袜aV先锋影院先| 无码+免费+国产| 91亚洲精选| 中文字幕综合在线| 66精品视频| 精品欧美在线| 人妻精品久久久久| y111111国产精品久久婷婷| 国产粉嫩无码不卡在线观看| 小蜜桃,午夜| 国产精品久久久99| 91人妻网| 欧美日韩有码| 无码少妇一区二区| 四虎在线免费观看视频| 国产精品自产拍在线观看55亚洲| 日本人妻精品视频| 综合网久久| 中文字幕爆乳JULIA女教师| 国产精品无码av在线| 免费看女乱人乱精网站| 亚洲欧美另类图片| 日韩精品观看| 人妻视频中文字幕| 一区二区三区伦理|